Phase III CheckMate-67T trial of subcutaneous Opdivo + hyaluronidase meets endpoints in advanced or metastatic ccRCC

EC approves Opdivo + Yervoy as first-line treatment for HCC

The European Commission approved Opdivo (nivolumab) plus Yervoy (ipilimumab) for the first-line treatment of adult patients with unresectable or advanced hepatocellular carcinoma.

March 14, 2025

Vol.51 No.10

Clinical Roundup

Opdivo + chemo improves OS in resectable lung cancer, phase III study shows

Bristol Myers Squibb announced the final analysis of overall survival from the phase III CheckMate-816 study, which evaluated Opdivo (nivolumab) in combination with platinum-doublet chemotherapy as a neoadjuvant treatment for adult patients with resectable (tumors ≥ 4 cm or node positive) non-small cell lung cancer.

February 21, 2025

Vol.51 No.07

Clinical Roundup

Opdivo + Yervoy show improvement in PFS for MSI-high, MMR- CRC in phase III trial

Bristol Myers Squibb announced results of an analysis from the three-arm phase III CheckMate-8HW trial evaluating Opdivo (nivolumab) plus Yervoy (ipilimumab) versus Opdivo monotherapy across all lines of therapy, including first-line, for the treatment of microsatellite instability-high/mismatch repair-deficient metastatic colorectal cancer. At a median follow-up of 47 months, Opdivo plus Yervoy demonstrated a statistically significant and clinically meaningful improvement in the dual-primary endpoint of progression-free survival as assessed by Blinded Independent Central Review versus Opdivo monotherapy (HR 0.62; 95% CI 0.48–0.81; P = 0.0003).

January 31, 2025

Vol.51 No.04

Drugs & Targets

FDA approves Opdivo and Opdivo Qvantig for subcutaneous injection

FDA approved Opdivo (nivolumab) and Opdivo Qvantig (hyaluronidase-nvhy) for subcutaneous injection across approved adult, solid tumor Opdivo indications as monotherapy, monotherapy maintenance following completion of Opdivo plus Yervoy (ipilimumab) combination therapy, or in combination with chemotherapy or cabozantinib.

January 10, 2025

Vol.51 No.01

Drugs & Targets

EC approves Opdivo + Yervoy as first-line treatment for MSI-H or dMMR metastatic CRC

The European Commission has approved Opdivo (nivolumab) plus Yervoy (ipilimumab) for the first-line treatment of adult patients with microsatellite instability-high or mismatch repair deficient unresectable or metastatic colorectal cancer.

January 10, 2025

Vol.51 No.01

Clinical Roundup

Imaging technique accurately detects ccRCC

A new study led by investigators from the UCLA Health Jonsson Comprehensive Cancer Center has demonstrated a new, non-invasive imaging technique can accurately detect clear-cell renal cell carcinoma, the most common form of kidney cancer.

October 04, 2024

Vol.50 No.37

Phase III CheckMate-67T trial of subcutaneous Opdivo + hyaluronidase meets endpoints in advanced or metastatic ccRCC

YOU MAY BE INTERESTED IN

EC approves Opdivo + Yervoy as first-line treatment for HCC

Opdivo + chemo improves OS in resectable lung cancer, phase III study shows

Opdivo + Yervoy show improvement in PFS for MSI-high, MMR- CRC in phase III trial

FDA approves Opdivo and Opdivo Qvantig for subcutaneous injection

EC approves Opdivo + Yervoy as first-line treatment for MSI-H or dMMR metastatic CRC

Imaging technique accurately detects ccRCC

Renew today!

Subscriber content

Never miss an issue!

Login